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Resistant hypertension? Time  
to consider this fourth-line drug 
For most adults with resistant hypertension, 
spironolactone is superior to doxazosin and bisoprolol  
as an adjunct to triple therapy.
PRACTICE CHANGER 
When a triple regimen of an ACE inhibitor or 
ARB, calcium channel blocker, and a thiazide 
diuretic fails to achieve the target blood pres-
sure, try adding spironolactone.
STRENGTH OF RECOMMENDATION
C: Based on a high-quality disease-oriented 
randomized controlled trial.1 
Williams B, MacDonald TM, Morant S, et al. Spironolactone versus 
placebo, bisoprolol, and doxazosin to determine the optimal treatment 
for drug-resistant hypertension (PATHWAY-2): a randomised, double-
blind, crossover trial. Lancet. 2015;386:2059–2068.
ILLUSTRATIVE CASE
Willie S, a 56-year-old with chronic essential 
hypertension, has been on an optimally dosed 
3-drug regimen of an ACE inhibitor, a calcium 
channel blocker, and a thiazide diuretic for 
more than 3 months, but his blood pressure is 
still not at goal.
What is the best antihypertensive agent 
to add to his regimen?
Resistant hypertension—defined as in-adequate blood pressure (BP) control despite a triple regimen of angioten-
sin-converting enzyme (ACE) inhibitor or 
angiotensin receptor blocker (ARB), calcium 
channel blocker (CCB), and thiazide diuret-
ic—affects an estimated 5% to 30% of those 
being treated for hypertension.1,2 Guidelines 
from the 8th Joint National Committee (JNC-
8) on the management of high BP, released 
in 2014, recommend beta-blockers, alpha-
blockers, or aldosterone antagonists (AAs) 
as equivalent choices for a fourth-line agent. 
The recommendation is based on expert 
opinion.3
Hypertension guidelines from the UK’s 
National Institute for Health and Care Excel-
lence, released in 2011, recommend an AA if 
BP targets have not been met with the triple 
regimen. This recommendation, however, 
is based on lower-quality evidence, without 
comparison with beta-blockers, alpha-block-
ers, or other drug classes.4
More evidence since guideline’s release
A 2015 meta-analysis of 15 studies and a total 
of more than 1200 participants (3 randomized 
controlled trials [RCTs], one nonrandom-
ized placebo-controlled comparative trial, 
and 11 single-arm observational studies) 
demonstrated the effectiveness of the AAs 
spironolactone and eplerenone on resistant 
hypertension.5 In the 4 comparative studies, 
AAs decreased office systolic blood pressure 
(SBP) by 24.3 mm Hg (95% confidence in-
terval [CI], 8.65-39.87; P=.002) and diastolic 
blood pressure (DBP) by 7.8 mm Hg (95% CI, 
3.79-11.79; P=.0001) more than placebo. 
In the 11 single arm studies, AAs reduced 
SBP by 22.74 mm Hg (95% CI, 18.21-27.27; 
P <.00001), and DBP by 10.49 mm Hg 
(95% CI, 8.85–12.13; P <.00001). 
The previous year, a randomized, pla-
cebo-controlled trial examined the effect of 
low-dose (25 mg) spironolactone compared 
with placebo in 161 patients with resistant 
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hypertension.6 At 8 weeks, 73% of those re-
ceiving spironolactone reached a goal SBP 
<140 mm Hg vs 41% of patients on pla-
cebo (P=.001). The same proportion (73%) 
achieved a goal DBP <90 mm Hg in the spi-
ronolactone group, compared with 63% of 
those in the placebo group (P=.223). 
Ambulatory BP was likewise assessed 
and found to be significantly improved among 
those receiving spironolactone vs placebo, 
with a decrease in SBP of 9.8 mm Hg (95% CI, 
-14.2 to -5.4; P<.001), and a 3.2 mm Hg de-
cline in DBP (95% CI, -5.9 to -0.5; P=.013).6
STUDY SUMMARY
First study to compare  
spironolactone with other drugs
The study by Williams et al—a double-blind, 
randomized placebo-controlled crossover 
trial conducted in the UK—was the first RCT 
to directly compare spironolactone with other 
medications for the treatment of resistant hy-
pertension in adults already on triple therapy 
with an ACE inhibitor or ARB, a CCB, and a thi-
azide diuretic.1 The trial randomized 335 indi-
viduals with a mean age of 61.4 years (age range 
18 to 79), 69% of whom were male; 314 were in-
cluded in the intention-to-treat analysis.1
Enrollment criteria for resistant hyper-
tension specified a clinic-recorded SBP of 
≥140 mm Hg (or ≥135 mm Hg in those with 
diabetes) and home SBP (in 18 readings over 
4 days) of ≥130 mm Hg.1 To ensure fidelity 
to treatment protocols, the investigators di-
rectly observed therapy, took tablet counts, 
measured serum ACE activity, and assessed 
BP measurement technique, with all partici-
pants adhering to a minimum of 3 months on 
a maximally dosed triple regimen. 
Diabetes prevalence was 14%; tobacco 
use was 7.8%; and average weight was 93.5 kg 
(205.7 lbs).1 Because of the expected inverse 
relationship between plasma renin and re-
sponse to AAs, plasma renin was measured at 
baseline to test whether resistant hyperten-
sion was primarily due to sodium retention.1
Participants underwent 4,  
12-week rotations  
All participants began the trial with 4 weeks 
of placebo, followed by randomization to 
12-week rotations of once daily oral treat-
ment with 1) spironolactone 25 to 50 mg, 
2) doxazosin modified release 4 to 8 mg, 
3) bisoprolol 5 to 10 mg, and 4) placebo.1 
Six weeks after initiation of each study medi-
cation, participants were titrated to the higher 
dose. There was no washout period between 
cycles. 
The primary outcome was mean SBP 
measured at home on 4 consecutive days 
prior to the study visits on Weeks 6 and 
12. Participants were required to have at least 
6 BP measurements per each 6-week period 
in order to establish a valid average. Primary 
endpoints included: the difference in home 
SBP between spironolactone and placebo, 
the difference in home SBP between spirono-
lactone and the mean of the other 2 drugs, 
and the difference in home SBP between spi-
ronolactone and each of the other 2 drugs.
❚ The results: Spironolactone lowered 
SBP more than placebo, doxazosin, and bi-
soprolol (TABLE),1 and clinic measurements 
were consistent with home BP readings. 
Overall, 58% of participants achieved 
goal SBP <135 mm Hg on spironolactone, 
compared with 42% on doxazosin, 44% on bi-
soprolol, and 24% on placebo.1 The effective-
Nearly 60% of 
trial participants 
achieved their 
target SBP on 
spironolactone. 
TABLE
Home SBP after 12 weeks of treatment1  
Treatment Mean SBP, mm Hg (95% CI) Change from baseline (95% CI)
Spironolactone 133.5 (132.3 to 134.8) -14.4 (-15.6 to -13.1)
Doxazosin 138.8 (137.6 to 140.1) -9.1 (-10.3 to -7.8)
Bisoprolol 139.5 (138.2 to 140.8) -8.4 (-9.7 to -7.1)
Placebo 143.7 (142.5 to 145) -4.2 (-5.4 to -2.9)
CI, confidence interval; SBP, systolic blood pressure.
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Only 1% of 
trial participants 
discontinued 
spironolactone 
due to adverse 
events. 
ness of spironolactone on SBP reduction was 
shown to exhibit an inverse relationship to 
plasma renin levels, a finding that was not ap-
parent with the other 2 study drugs. However, 
spironolactone had a superior BP lowering 
effect throughout nearly the entire renin dis-
tribution of the cohort. The mean difference 
between spironolactone and placebo was 
-10.2 mm Hg; compared with the other drugs, 
spironolactone lowered SBP, on average, by 
5.64 mm Hg more than bisoprolol and doxa-
zosin; 5.3  mm Hg more than doxazosin alone, 
and 5.98 mm Hg more than bisoprolol alone.
Only 1% of trial participants had to dis-
continue spironolactone due to adverse 
events—the same proportion of withdrawals 
as that for bisoprolol and placebo and 3 times 
less than for doxazosin.1 
WHAT’S NEW
Evidence of spironolactone’s superiority
This is the first RCT to compare spironolac-
tone with 2 other commonly used fourth-line 
antihypertensives—bisoprolol and doxazo-
sin—in patients with resistant hypertension. 
The study demonstrated clear superiority of 
spironolactone in achieving carefully mea-
sured ambulatory and clinic-recorded BP 
targets vs a beta-blocker or an alpha-blocker. 
CAVEATS
Findings do not apply across the board
Spironolactone is contraindicated in patients 
with severe renal impairment. Although mul-
tiple drug trials have demonstrated the drug’s 
safety and effectiveness, especially in pa-
tients with resistant hypertension, we should 
factor in the need for monitoring electrolytes 
and renal function within weeks of initiating 
treatment and periodically thereafter.7,8 In 
this study, spironolactone increased potas-
sium levels, on average, by 0.45 mmol/L.  No 
gynecomastia (typically seen in about 6% of 
men) was found in those taking spironolac-
tone for a 12-week cycle.1
This single trial enrolled mostly Cau-
casian men with a mean age of 61 years. Al-
though smaller observational studies that 
included African American patients have 
shown promising results for spironolactone, 
the question of external validity or applicabil-
ity to a diverse population has yet to be deci-
sively answered.9
CHALLENGES TO IMPLEMENTATION
Potential for adverse reactions,  
lack of patient-oriented results
The evidence supporting this change in prac-
tice has been accumulating for the past few 
years. However, physicians treating patients 
with resistant hypertension may have con-
cerns about hyperkalemia, gynecomastia, and 
effects on renal function. More patient-orient-
ed evidence is likewise needed to assist with 
the revision of guidelines and wider adoption 
of AAs by primary care providers.                JFP
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